COMPASS Pathways' (CMPS) In-Line Rating Reiterated at Evercore ISI

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "in-line" rating reaffirmed by equities researchers at Evercore ISI in a research note issued on Monday, Marketbeat.com reports. They currently have a $6.00 price target on the stock, down from their previous price target of $11.00. Evercore ISI's target price indicates a potential upside of 140.48% from the company's previous close.

A number of other analysts have also recently commented on the company. HC Wainwright restated a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a research report on Monday, May 12th. Cantor Fitzgerald reiterated an "overweight" rating and set a $12.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, May 27th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group lowered their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

COMPASS Pathways Stock Performance

Shares of CMPS traded down $2.14 on Monday, reaching $2.50. The company's stock had a trading volume of 10,760,351 shares, compared to its average volume of 984,020. COMPASS Pathways has a 12-month low of $2.37 and a 12-month high of $8.54. The stock has a market capitalization of $233.43 million, a P/E ratio of -1.28 and a beta of 2.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. The stock's 50 day simple moving average is $4.09 and its two-hundred day simple moving average is $3.89.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03. Research analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Institutional investors have recently made changes to their positions in the business. Cerity Partners LLC purchased a new position in COMPASS Pathways in the 1st quarter worth approximately $29,000. GAMMA Investing LLC raised its position in shares of COMPASS Pathways by 93.6% during the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after buying an additional 5,003 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in shares of COMPASS Pathways in the fourth quarter worth $43,000. Ethos Financial Group LLC bought a new position in shares of COMPASS Pathways during the first quarter worth $35,000. Finally, Conservest Capital Advisors Inc. boosted its position in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after acquiring an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.